A number of cancers possess constitutive activity of the dsRNA-dependent kinase, PKR. Inhibition of PKR in these cancers leads to tumor cell death. We recently reported the increased presence of PKR phosphorylated on Thr451 (p-T451 PKR) in clinical samples from myelodysplastic syndrome (MDS) patients and acute leukemia cell lines. Whereas p-T451 PKR in low-risk patient samples or PTEN-positive acute leukemia cell lines was mostly cytoplasmic, in high-risk patient samples and acute leukemia cell lines deficient in PTEN, p-T451 PKR was mainly nuclear. As nuclear activity of PKR has not been previously characterized, we examined the status of nuclear PKR in acute leukemia cell lines. Using antibodies to N-terminus, C-terminus and the kinase domain in conjunction with a proteomics approach, we found that PKR exists in diverse molecular weight forms in the nucleus. Analysis of PKR transcripts by reverse transcriptase-PCR, and PKR-derived peptides by MS/MS revealed that these forms were the result of post-translational modifications (PTMs). Biochemical analysis demonstrated that nuclear PKR is an active kinase that can respond to stress. Given the association of PKR with PTEN and the Fanconi complex, these results indicate that PKR likely has other previously unrecognized roles in nuclear signaling that may contribute to leukemic development.
Introduction
The dsRNA-dependent protein kinase, PKR, an innate immune/ inflammatory cytokine associated protein kinase, belongs to the eukaryotic translation initiation factor 2 subunit a (eIF2a) kinase family.
1,2 PKR is activated in response to diverse stress signals. In addition to phosphorylating eIF2a, PKR has been demonstrated to phosphorylate and regulate p53, inhibitor kB kinase, the B56a regulatory subunit of protein phosphatase 2A, RNA helicase, insulin receptor substrate-1 and cell division cycle-2. [3] [4] [5] [6] Recent data indicate that PKR is required for the tumor suppressor function of PTEN. PTEN, through its PDZ domain and independent of phosphatase activity, was demonstrated to enhance cytoplasmic activation of PKR. 7 In contrast, enhanced PKR activity has been reported in acute leukemia, colon, breast, lung and prostate cancer cell lines, which are deficient in PTEN, as well as patient samples from breast carcinoma, colon cancer, melanoma and diverse hematological malignancies. [8] [9] [10] [11] [12] [13] Cancers possessing enhanced PKR activity are highly susceptible to inhibition of PKR. 8, 13, 14 Although PKR has been identified in nuclear and cytoplasmic fractions, most activities attributed to PKR occur in the cytoplasm; hence, the role of nuclear PKR has remained unclear. Jeffrey et al. 15 found, in NIH3T3 cells overexpressing exogenous PKR and Daudi Burkitt's lymphoma cells treated with interferon, the ratio of cytoplasmic to nuclear PKR to be 5:1. Both nuclear and cytoplasmic PKR were reported to be 68 kDa; the only difference was in post-translational modification (PTM). Whereas, cytoplasmic PKR presented with multiple isoelectric points (pIs), nuclear PKR presented with a single, basic pI, suggesting this protein was not highly phosphorylated. 15 Recent studies have attributed clinical and pathological significance to nuclear PKR. 9, 13, 16 We initially reported that CD34 þ cells from myelodysplastic syndrome (MDS) patients contain elevated levels of p-T451 PKR as compared with controls. 9 Whereas, p-T451 PKR was observed in the cytoplasm of low-risk MDS samples, it was predominantly nuclear in high-risk samples. The presence of nuclear p-T451 PKR was concurrent with increases in p-S473 AKT and p-S2448 mTOR levels and a general decrease in PTEN levels. 17, 18 In total, 14 phosphorylation sites have been identified in PKR; 12 have been biochemically verified, and eight have been functionally characterized. [19] [20] [21] [22] [23] [24] Although phosphorylation of most sites serves to augment kinase activity toward eIF2a, only phosphorylation of T451 is required to generate an active kinase. 19, 20 This suggests that increases in nuclear p-T451 PKR might correlate with increases in nuclear PKR activity. As all previous reports of nuclear p-T451 PKR employed only immunocytochemical or basic western blotting techniques, we sought to characterize nuclear PKR in acute leukemia cell lines in which we demonstrated a requirement for PKR activity for proliferation and survival. 8 Using both proteomic and biochemical approaches, we demonstrate that there are diverse molecular weight and post-translationally modified forms of PKR in the nuclear compartment of acute leukemia cells, and that nuclear PKR is an active kinase which responds to stress. These data add significance to the clinical findings of p-T451 PKR in the nucleus and suggest a more direct role for PKR in nuclear signaling. 
Materials and methods

Cell culture and inhibitors
Protein extraction and western blotting
Cells were lysed and protein was analyzed as described. 8 Primary antibodies were as follows (from Cell Signaling Laboratories, Danvers, MA, USA: a-p-T451 PKR (1:1000); Santa Cruz Biotechnologies, La Jolla, CA, USA: a-PKR (D-20; 1:1000), a-PKR (K-17; 1:1000), a-eIF2a (FL-315; 1:1000) and a-lamin B (1:1000); Abcam, Cambridge, UK: a-N-terminal PKR (ab58301; 1:500) and a-C-terminal PKR (ab28943; 1:500) or Sigma-Aldrich, St Louis, MO, USA: a-p-T451 PKR (1:1000) and a-b-tubulin (1:5000)). Secondary antibodies (Santa Cruz Biotechnologies) were diluted 1:10 000 in 3% BSA in PBST or 1:2000 in nonfat dry milk in PBST (p-T451 PKR).
Immunocytochemistry
Immunocytochemistry was performed as described. 18 The antibodies a-p-T451 PKR and a-PKR (D20) were used at 1:200 and 1:500, respectively.
Cellular fractionation and isolation of nuclei
Cells (5-10 Â 10 6 ) were washed and resuspended in hypotonic swelling buffer (10 mM HEPES, pH 7.5, 1.5 mM MgCl 2 and 10 mM KCl). The suspension was passed 25-30 times through a 27-gauge needle with syringe. Fractions were isolated by centrifugation: (centrifugation 1) 400 Â g for 5 min (intact cells); (centrifugation 2) 2000 Â g for 10 min (nuclear fraction) and (centrifugation 3) 10 000 Â g for 15 min (heavy membrane). Supernatant following centrifugation 3 was saved as the cytoplasmic fraction. Pellets were lysed in gold lysis buffer as described above. For purification of nuclei, cell pellets were resuspended in hypotonic buffer (10 mM Tris-HCl, pH 7.5, 5 mM MgCl 2 and 10 mM NaCl). Triton X-100 (10% stock) was added at a concentration of 0.3%. The suspension was passed twice through a 22-gauge needle with syringe and centrifuged at 800 Â g for 10 min at 4 1C. The supernatant was centrifuged to remove debris. Protease/phosphatase inhibitor cocktails (Roche, Milan, Italy) and glycerol (15%) were added (cytosolic fraction). Nuclei were lysed as described above.
Two-dimensional (2-D) gel electrophoresis
Whole cells or nuclei were lysed in 2 M thiourea, 7 M urea, 4% CHAPS, 0.8% IPG buffer pH 3-10 (Bio-Rad Laboratories Inc., CA, USA) and benzonase plus protease/phosphatase inhibitors. Lysates were centrifuged at 21 000 Â g for 1 h at 4 1C. Protein concentration was determined as described. 8 IPG gel strips (IPG ReadyStrip (pH 3-10) length 7 cm, Bio-Rad Laboratories Inc.,) were rehydrated in swelling solution (7 M urea, 2 M thiourea, 4% CHAPS, 100 mM dithiothreitol and 0.2% anfoline) containing 500 mg of protein for 16 h at 20 1C. Isoelectric focusing was carried out for 30 min at 500 V (gradient), 60 min at 500 V (gradient), 60 min at 1000 V (gradient) and 4000 V to reach a total of 80 kVh. Strips were equilibrated twice with 50 mM Tris-HCl, pH 8.8, 6 M urea, 30% glycerol, 2% SDS and 0.5% dithiothreitol (equilibration 1) or 4.5% iodoacetamide (equilibration 2). Separation in the second dimension was performed with 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Gels were transferred to nitrocellulose and immunoblotted as described above.
Liquid phase ion-exchange chromatography
Whole cells or nuclei were solubilized in lysis buffer (50 mM Tris base, 7 M urea, 2 M thiourea, 4% (w/v) n-octyl b-dglucopyranoside and 10 mM (tris(2-carboxyethyl)phosphine)) containing protease/phosphatase inhibitors. Buffer was exchanged using a PD 10 desalting column. Protein quantification was performed as stated above. Proteins were separated in the first dimension by chromatofocusing, performed on an HPCF-1D column. Sample buffer was added to aliquots from each fraction and subjected to 10% SDS-PAGE. Gels were transferred to nitrocellulose and immunoblotted as described above.
PKR kinase assay
Kinase assays were performed as stated, 25 with the following additions: myelin basic protein or Flag-eIF2a was used as a substrate. For assays using the PI, immunoprecipitates were incubated in 2 Â PKR kinase buffer with PI for 5 min on ice before the addition of substrate, cold ATP and g-[
Reactions were stopped by the addition of sample buffer. Samples were separated by 12% SDS-PAGE, transferred to nitrocellulose and exposed to Kodak autoradiograph film (Kodak, Rochester, NY, USA). Blots were immunoblotted with a-N-ter hPKR, a-PKR (D20) or a-eIF2a antibody as described above.
Mass spectrometry analysis of immunoprecipitated nuclear PKR
Nuclei were lysed in RIPA buffer containing protease/phosphatase inhibitors and immunoprecipitated (see Supplementary Material). Immunoprecipitates were separated by 10% SDS-PAGE and the gels were Coomassie blue stained. Individual lanes were fractionated into 2 mm slices. Gel slices were washed in 100 mM ammonium bicarbonate (pH 8) and 50% acetonitrile to destain, and then digested overnight with sequencing grade trypsin (Promega, Madison, WI, USA). Peptides were extracted, dried down, and resuspended in 2% (v/v) acetonitrile, 0.1% (v/v) formic acid. An aliquot was loaded onto a QTOF G6520 (Agilent Technologies Inc., Santa Clara, CA, USA), equipped with a 1200 series capillary pump, a 1200 series nano pump and the Chip Cube system. The LC-Chip (Agilent) was constituted of a Zorbax 300SB-C18 enrichment column (4 mm Â 40 nl, 5 mm) and a Zorbax 300SB-C18 analytical column (75 Â 43 mm, 5 mm). Elution was performed by a solvent mixture composed of 3% (v/v) acetonitrile, 0.1% (v/v) formic acid (solvent A) and 97% (v/v) acetonitrile, and 0.1% formic acid (solvent B). Data were acquired in data-dependent tandem mass spectrometry (MS/MS) mode. Mass spectra were processed and analyzed using Mascot v.2.2 against the UniProt-SwissProt database.
Reverse transcriptase-PCR of PKR mRNA
Total RNA isolation, first strand synthesis, PCR and analysis were performed as described previously. 26 Primer pairs were as follows: N-terminus: 
Results
Acute leukemia cell lines contain diverse forms of PKR
We examined the level and localization of p-T451 PKR in the PTEN-positive HL60 27, 28 and PTEN-negative CCRF-CEM (CEM) cell lines 29 using immunocytochemistry. Similar to what was observed in MDS patient samples, 9, 17, 18 lack of PTEN correlated with increased p-T451 PKR in the nucleus (Figure 1a ). To better , from cytoplasmic and nuclear lysates of untreated CEM cells or immunoprecipitations from the nuclear lysate using a-N-ter hPKR (antigen: aa1-101 of hPKR), a-PKR (D20) (antigen: aa458-508 of mPKR), a-hPKR (K17) (antigen: C-terminus of hPKR), a-C-ter hPKR (antigen: aa502-551 of hPKR) and a-p-T451 PKR, was separated by 10% SDS-polyacrylamide gel electrophoresis, transferred and immunoblotted with the indicated antibody. The data are representative of at least three independent experiments.
Nuclear activation of PKR in acute leukemia WL Blalock et al quantify and characterize the difference between cytoplasmic and nuclear p-T451 PKR, we fractionated HL60, THP-1, CEM and Jurkat cells and examined p-T451 PKR and PKR expression by western blotting (Figure 1b ). In each cell line, two distinct forms of PKR reacted with a-p-T451 PKR antibody. The upper band migrated as a 72 kDa protein and was preferentially cytoplasmic, while the lower band migrated as a 60 kDa protein and was preferentially nuclear. Similarly, western blotting using a-PKR (D20) antibody revealed two major bands between 50 and 75 kDa. The upper band, which was preferentially cytoplasmic, migrated as a 68 kDa protein, while the lower band, was preferentially nuclear, and migrated as a 62 kDa protein.
As a-PKR (D20) was raised against an oligopeptide in the C-terminal half of mouse PKR (Tik), which shares 72% identity to human PKR, we sought to test the specificity of a-PKR (D20) in lysates from CEM, using an antibody screen. Nuclear lysates, cytoplasmic lysates or immunoprecipitates from nuclear lysates, using a-N-ter hPKR, a-PKR (D20), a-hPKR (K17), a-C-ter hPKR or a-p-T451 PKR, were separated by SDS-PAGE and immunoblotted with either a-N-ter hPKR or a-PKR (D20). In nuclear and cytoplasmic lysates, both a-N-ter hPKR and a-PKR (D20) recognized two different molecular weight forms of PKR.
Although a-N-ter hPKR preferentially recognized the 68 kDa form, a-PKR (D20) showed preferential affinity for the 62 kDa form. All the antibodies immunoprecipitated both forms of PKR to some degree, but a-PKR (D20) was the only antibody to preferentially immunoprecipitate the 62 kDa form (Figure 1c ; Supplementary Figure 1 ).
The 62 kDa (p-60 kDa) PKR does not result from alternative splicing
As splice variants of PKR have been reported, 30 alternative mRNA splicing of the PKR coding region was examined using nested PCR (Figure 2 ). Nested PCR amplified a single band of the expected size in each PCR reaction. Additional bands were also visible in some reactions, but were attributed to products of degenerative PCR as they constituted a minor fraction of the product and did not result in the expected deletion of 150-250 nucleotides required to shift PKR by 6-8 kDa.
Nuclear PKR exists in multiple post-translationally modified forms
We next examined PKR in CEM cells using 2-D electrophoresis (Figures 3a-d) . Blotting with a-p-T451 PKR revealed at least eight pIs between pH 5.2 and 9.2 for the 72 kDa form of p-T451 PKR and three pIs between pH 6.5 and 7.2 for the 60 kDa form of p-T451 PKR in whole-cell lysates (Figure 3a) . A similar distribution of pIs corresponding to PKR was detected by a-PKR (D20) in whole-cell lysates (Figure 3b) . Although a-PKR (D20) detected several higher molecular weight proteins with acidic pIs in whole-cell lysates, these were not detectable in nuclear lysates (Figures 3b and d) . In contrast, blotting of nuclear lysates revealed that the majority of nuclear p-T451 PKR was the 60 kDa form represented by nine pIs between pH 6.5 and 9.0 (Figure 3c) . A similar pattern was seen following immunoblotting with a-PKR (D20) (Figure 3d ). To better determine individual pIs for the diverse forms of nuclear PKR, nuclear lysates were fractionated on an ion-exchange column by FPLC. Individual fractions between pH 8.2 and 4.0 were separated by SDS-PAGE and immunoblotted with a-PKR (D20). In agreement with 2-D analysis and western blotting, most PKR detected was of the lower form, which eluted in two main phases; between pH 8.2 and 8.0 and around 6.0 (Figure 3e) .
Nuclear PKR is an active kinase PKR was immunoprecipitated from nuclear lysates of unstimulated CEM cells, using a-N-ter hPKR, a-PKR (D20) or a Figure 2 Diverse forms of PKR are not a result of alternate mRNA splicing. Nested reverse transcriptase-PCR was carried out as described in 'Materials and methods' in HL60, HL60/vector, HL60/ PI3K, THP-1, CCRF-CEM, Jurkat and Molt-4 cells using primer pairs covering exons coding for N-terminal PKR, the internal region of PKR, and C-terminal PKR. The data presented are representative of three independent experiments. Exons denoted with a hash (that is, 10/11) indicate the primer hybridization site covered sequences in both exons.
Nuclear activation of PKR in acute leukemia WL Blalock et al non-specific IgG antibody (control). The immunoprecipitate was used in an in vitro kinase assay using myelin basic protein as a substrate. Anti-PKR immunoprecipitates contained between two-and five-fold more kinase activity than the control (Figure 4a ). Whereas, a-PKR (D20) immunoprecipitates contained the most activity as measured by myelin basic protein phosphorylation, a-N-ter hPKR immunoprecipitates contained the most autophosphorylation activity (Figure 4a) .
To determine whether the observed activity was specific to PKR, the ability of the commercial PI to inhibit kinase activity was assayed in a series of immunoprecipitations with a-N-ter hPKR and a-PKR (D20). Before the kinase assay, immunoprecipitates were incubated with serial dilutions of PI. Under our assay conditions, PI demonstrated an IC 50 between 10 and 50 mM in both sets of immunoprecipitations (Figures 4b-c) . PI is a reversible, competitive inhibitor that binds the ATP-binding site of PKR so that the IC 50 is relative to the concentration of free ATP. When taken into account that our in vitro assay contained 100-fold more free ATP than assays reported by Jammi et al. 31 ; our results indicated that PI reduced kinase activity with an IC 50 similar to that previously reported for PKR (100-210 nM).
As eIF2a is the canonical PKR substrate, the ability of nuclear PKR to phosphorylate purified Flag-eIF2a was tested (Figure 4d ). Although PKR activity directed toward eIF2a was much greater in a-N-ter hPKR immunoprecipitates, immunoprecipitates using a-PKR (D20) led to modest increases in phosphorylated Flag-eIF2a, which were inhibited with PI (Figures 4d and e) .
Nuclear PKR is activated by stress
The ability to stimulate nuclear PKR activity in response to a DNA damaging agent (mitomycin C) or general stressing agent (H 2 O 2 ) was examined in CEM, Jurkat and THP-1 cells. As elevated nuclear PKR activity was already apparent in unstimulated Jurkat and CEM cells (2-to 2.5-fold more than THP-1 cells, respectively), stress-induced augmentation in PKR activity was rarely observed to increase over twofold (Figure 1b ; Supplementary Figure 2 ). In contrast, augmentation of PKR activity in THP-1 cells following stress was easily observed.
In response to mitomycin C, PKR activity immunoprecipitated with a-PKR (D20) from nuclear lysates increased 2.3-fold in 4 h whereas activity associated with a-N-ter PKR immunoprecipitates decreased (Figure 5a, left) . In contrast, an increase in activity (between 1.5-and 2.5-fold) was associated with a-N-ter hPKR and a-PKR (D20) immunoprecipitates in cytoplasmic lysates (Figure 5a , right). Following treatment with H 2 O 2 , a slight decrease in activity associated with a-PKR (D20) immunoprecipitates from nuclear lysates was observed while a slight increase in activity (1.3-fold) was associated with a-N-ter hPKR immunoprecipitates (Figure 5b, left) . In cytosolic lysates, PKR activity associated with a-N-ter hPKR and a-PKR (D20) augmented by 1.8-fold in 4 h (Figure 5b, right) . In agreement with these observations, nuclear autophosphorylation activity associated with a-N-ter hPKR immunoprecipitates was significantly greater following H 2 O 2 versus mitomycin C treatment Statistical analysis was performed using a two-way Student's t-test. *Po0.05; **Po0.01. (d) PKR was immunoprecipitated from 250 mg of untreated CEM nuclear lysate using the indicated antibody. The immunoprecipitate was assayed in an in vitro kinase assay using g-[
32 P]-ATP as a phosphate donor to phosphorylate Flag-eIF2a. 'Control': purified Flag-eIF2a substrate. Reactions were separated by 10% SDS-PAGE, transferred to nitrocellulose and exposed to film. The membranes were immunoblotted with a-eIF2a antibody. Fold activity is presented as the ratio of change in Flag-eIF2a phosphorylation from the respective IgG control and the change in Flag-eIF2a. (e) PKR was immunoprecipitated from 250 mg of untreated or H 2 O 2 treated (100 mM, 4 h) CEM nuclear lysate using a-PKR (D20) antibody. The immunoprecipitate was assayed in an in vitro kinase assay as stated in (d). Immunoprecipitates treated with the PI were incubated for 5 min with 1 mM PI before the kinase assay. Membrane was immunoblotted with a-N-ter hPKR. Fold change in activity was determined as a ratio in the change of phosphorylated Flag-eIF2a versus the amount of PKR immunoprecipitated. Data in (d) and (e) are representative of three (n ¼ 3) independent experiments.
( Figure 5c ). Representative blots are presented in Supplementary  Figure 3 .
PKR is present at diverse molecular weights in the nucleus
To verify the presence of PKR at the molecular weights, wherein a-p-T451 PKR, a-N-ter hPKR and a-PKR (D20) detected bands in western and 2-D analysis, PKR was immunoprecipitated from untreated CEM nuclear lysates using a-N-ter hPKR. The immunoprecipitates were separated by SDS-PAGE, Coomassie stained, and the gel lanes fractionated between 100 and 37 kDa, as described in 'Materials and methods'; then analyzed by mass spectrometry. Each gel slice was treated as an independent sample of its respective MW range. MS/MS analysis identified PKR in gel fractions corresponding to 75-69, 69-63, 63-57, and 57-50 kDa. PKR was not identified in any gel fraction above 75 kDa or below 50 kDa. Moreover, PKR was the only kinase identified. Table 1 lists the individual peptides from Mascot unique to PKR which were identified in MS/MS, with a minimum confidence score of 95%, the Mascot score, percent coverage of the PKR sequence (%cov), and the molecular weight range of the gel fragment (MWexp) in which they were recovered. Figure 6 shows the location, within the primary amino acid sequence of PKR, of individual peptides listed in Table 1 . Molecular weights for the gel fragments wherein PKR was identified by MS/MS, corresponded well to the individual bands visualized in western and 2-D analysis (Figures 1b, c and 3 ).
Discussion
Onuki et al., 32 first documented phosphorylated nuclear PKR (p-T446) in tunicamycin-treated human neuroblastoma cells. Since then, additional groups have reported nuclear p-T451 PKR or elevation in the level of PKR localized to the nucleus, in acute leukemia, MDS, melanoma, breast, colon, prostate and lung cancer patient samples or cell lines, as well as neurocytes from advanced Creutzfeldt-Jakob disease patients. 8, 9, 13, 16 Unfortunately, as many of these studies were performed with patient material, the extent of actual PKR kinase activity in the nucleus was not examined.
Nuclear PKR may serve to maintain genomic integrity. PKR interacts with members of the Fanconi DNA repair complex, and loss of PKR is associated with enhanced cell death following DNA damage induced by irradiation or chemotherapeutic compounds. 33, 34 A recent finding that PKR is required for PTEN function also supports a role for PKR in the nucleus.
PTEN, a major tumor suppressor, is responsible for the conversion of phosphatidylinositol-3,4,5-phosphate to phosphotidylinositol-4,5-phosphate in both cytoplasmic and nuclear compartments. 35 Loss of PTEN is associated with enhanced phosphatidylinositol-3,4,5-phosphate levels and constitutive activation of the AKT-mTOR pathway. Much of the PTEN in the cell is located in the nucleus, wherein it controls nuclear and chromosomal integrity. 35 Through its PDZ domain, PTEN represses Bmi-1 activity in the nucleus. 36 Bmi-1 functions indirectly to suppress the expression of p14
Arf , a cell cycle regulator responsible for the displacement of PKR from nucleophosmin and subsequent redistribution of active PKR. 36, 37 Often, PTEN is deleted or its expression suppressed in cells wherein accumulation of PKR in the nucleus or nuclear p-T451 PKR is observed. 9, 13, 17, 18 In cell lines wherein nuclear p-T451 PKR is observed, PKR activity is constitutively elevated, and inhibition of PKR activity results in growth arrest and apoptosis. 8, 13, 14 This is unexpected for a pro-apoptotic kinase.
Here, we demonstrate that nuclear PKR is post-translationally modified on multiple sites and represents an active kinase that is further induced in response to stress. Most nuclear p-T451 PKR migrated closer to the theoretical molecular weight of PKR (62 kDa). The difference in the predicted electrophoretic mobility of PKR of 62 kDa and the observed 68 kDa has never been clarified. Our results did not reveal any alternate mRNA splicing products ruling out the possibility of the 62 kDa (p-60 kDa) form resulting from this mechanism. Additionally, alternate translation initiation may result in truncated forms of PKR.
Other than the predicted initiating codon, two additional inframe AUG's are present in the first 100 amino acids (M11 and M98). Although initiation at M11 could not account for a 6-8 kDa shift, initiation at M98 would produce a protein devoid of the a-N-ter hPKR epitope (within aa1-101). Additional unconventional initiation sites are also predicted at L30 (CUG) and L87 (UUG). Again, initiation at L30 could not account for a 6-8 kDa shift, and a peptide containing aaY27-R39 was identified in MS/MS in the 63-57 kDa range ruling out initiation at L87 (Table 1; Figure 6 ). Protein degradation was also not likely to yield this form. The 62 kDa form was preferentially nuclear and both western and 2-D analysis failed to identify any smearing or streaking between p68 (p-p72) and p62 (p-p60) bands/spots as would be expected for proteolytic degradation; instead each form of PKR presented as a distinct band. MS/MS supported western and 2-D data as no PKR peptides were observed outside the molecular weight ranges wherein PKR was evidenced with immunoblotting. On the other hand, we did not rule-out PTMs. It is possible p68 (p-p72) PKR is a result of hyperphosphorylation, although p62 and p-p60 forms of PKR presented with greater than eight different pIs in 2-D analysis without changing the apparent molecular weight. Alternatively, p68 (p-p72) PKR may result from ISGylation, 38 SUMOylation or ubiquitination. Such modifications to the C-terminal half of PKR could explain the decreased affinity of a-PKR (D20) for p68. Additional studies are required to determine specific PTMs of each form.
The p68 (p-p72) and p62 (p-p60) forms of PKR responded preferentially to stresses in a particular cellular compartment (p68 to general stress and p62 to nuclear stress); although protein levels of both forms were observed to increase in the nucleus following stress (Supplementary Figure 4) . The data suggest that as p-p60 PKR is already present and more abundant in the nucleus (see Figures 1b and 3c) , this form may be more adapted to general nuclear PKR activities or responding to nuclear stresses. The lack of a PTM may favor the localization of this form in the nucleus, although p62 (p-p60) PKR can be found in the cytoplasm following prolonged stress (unpublished results). It would be expected that prolonged nuclear stress would also eventually lead to substantial p68 (p-p72) PKR activation and migration to the cytoplasm and subsequent apoptosis. In contrast to p62 (p-p60) PKR, the PTM(s) present in p68 (p-p72) PKR may facilitate its nuclear export, making this form ideal for responding to cytoplasmic and cytotoxic stresses. Such a model would suggest that a balance must be achieved between the synthesis of p62 PKR and its modification to p68. Moreover, p62 and p68 showed differing activity toward Flag-eIF2a, which may be indicative of a difference in substrate selectivity between these two forms. Previous work demonstrated that indeed, in addition to phosphorylation of T451, phosphorylation of T446 is required for substrate recognition and phosphorylation of eIF2a, while p-T451 PKR can phosphorylate other substrates in the absence of T446 phosphorylation. 22 Whether p-p60 PKR is phosphorylated on T446 still remains to Abbreviations: %cov, the percent coverage of the protein for all identified peptides; Mwexp, the observed experimental molecular weight range was calculated based on extrapolation of the molecular weight markers and the location of the gel slice in which the peptide was identified; MWt, theoretical molecular weight for human PKR in the UniProt-SwissProt database. Data are representative of the results from three independent analyses coming from biological replicates. Peptides listed are unique to PKR and were identified by Mascot analysis of the mass spectra with a minimum confidence score of 95%. Figure 6 PKR is present in the nucleus at diverse molecular weights. Unique PKR peptides from Mascot, identified at a minimum confidence score of 95% by tandem mass spectrometry from all gel slices analyzed (100-37 kDa) are highlighted in the primary amino acid sequence of hPKR. The exact molecular weight range in which a specific peptide was recovered is listed in Table 1. be determined as does the other modifications present in each of these forms.
Our findings demonstrate that nuclear PKR has kinase activity, suggesting a role for PKR in nuclear signaling. Substrates for nuclear PKR remain to be characterized. MS/MS analysis identified several novel proteins that coimmunoprecipitated with PKR in addition to proteins known to associate, such as nucleophosmin and HSP70. Additional studies are required to assess which proteins truly interact with nuclear PKR. In addition, identification and characterization of the different PTMs between p62 (p-p60) and p68 (p-p72) should allow for a better dissection of the mechanism by which these two forms respond differently to nuclear and cytoplasmic stresses, thus yielding answers to the questions: (1) why does p-T451 PKR accumulate in the nucleus of high-risk MDS and certain acute leukemia cells, (2) why are cancer cells that maintain elevated PKR activity sensitive to PKR inhibition, and (3) what role does PKR and the inflammatory pathways that activate it have in neoplastic disease progression.
